These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35060407)

  • 21. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015.
    Hammond ER; Desta B; Near AM; Wang X; Jiang M
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34556546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 23. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 25. Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research.
    Feldman C; Curtis JR; Oates JC; Yazdany J; Izmirly P
    Lupus Sci Med; 2024 Oct; 11(2):. PubMed ID: 39401954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study.
    Huang SP; Guisinger A; Averell C; Bell CF; Rubin B
    Rheumatol Ther; 2023 Jun; 10(3):551-562. PubMed ID: 36738424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study.
    Rubin B; Chen Y; Worley K; Rabideau B; Wu B; Chang R; DerSarkissian M
    Rheumatol Ther; 2024 Aug; 11(4):947-962. PubMed ID: 38847995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany.
    Ding B; Pignot M; Garal-Pantaler E; Villinger B; Schefzyk S; Desta B; Stirnadel-Farrant HA; Schwarting A
    Rheumatol Ther; 2024 Apr; 11(2):285-299. PubMed ID: 38252212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
    Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
    J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
    [No Abstract]   [Full Text] [Related]  

  • 30. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
    Bell CF; Blauer-Peterson C; Mao J
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
    [No Abstract]   [Full Text] [Related]  

  • 31. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
    Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
    Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature.
    Arnaud L; Furie R; Morand EF; Aringer M; Peschken C; Desta B; Rapsomaniki E; Hedberg J; Knagenhjelm J; Seo C; Grünfeld Eén T; Sorrentino A; Tummala R; Stirnadel-Farrant HA; Ding B
    Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38123459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
    Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
    Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
    Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
    Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis.
    Heresi G; Dean B; Wu B; Lee H; Sketch MR; Stafkey-Mailey D; Morland K; Classi P; Spikes L
    BMC Pulm Med; 2024 Jul; 24(1):335. PubMed ID: 38992626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.